智通财经APP讯，微泰医疗-B(02235)公布2025年中期业绩，营业收入约2.46亿元，同比增长63.1%;毛利约1.27亿元，同比增长57.7%;母公司拥有人应占亏损约229.27万元，同比收窄93.9%;每股亏损 0.005元。
公告称，收入和毛利的显著增长主要归因于持续葡萄糖监测系统国内和国际销量的迅速提升。
净亏损减少主要由于公司销售规模的扩大，全面预算管控深化及精细化管理带来的运营效率提升。
智通财经APP讯，微泰医疗-B(02235)公布2025年中期业绩，营业收入约2.46亿元，同比增长63.1%;毛利约1.27亿元，同比增长57.7%;母公司拥有人应占亏损约229.27万元，同比收窄93.9%;每股亏损 0.005元。
公告称，收入和毛利的显著增长主要归因于持续葡萄糖监测系统国内和国际销量的迅速提升。
净亏损减少主要由于公司销售规模的扩大，全面预算管控深化及精细化管理带来的运营效率提升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.